Halozyme Therapeutics, Inc.

HALONASDAQHealthcare● Active

$70.73

$-0.80(-1.12%)

Market Cap$8.4B

P/E Ratio—

52W High$82.22

52W Low$51.06

Avg Volume1.6M

Open$71.59

Beta0.87

Free Cash Flow Financials Revenue

Halozyme Therapeutics, Inc. (HALO) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

HALO · free cash flow · updated Jun 8, 2026

Core FCF metrics

HALO · FCF · TTM · margin & CAGR

Free cash flow was $644.6M for FY2025 (fiscal year ending 2025-12-31), up 37.6% year-over-year The FCF margin was 46.1%. Five-year CAGR stands at +64.8%.

FY2025 Free Cash Flow$644.6M▲ +37.6% YoY

Trailing 12M (TTM)$667.7Mtrailing 4 quarters sum

FCF Margin46.1%$644.6M ÷ revenue

3-Year CAGR+39.9%FY2022 → FY2025

5-Year CAGR+64.8%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

HALO · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$651.6M(7M)$644.6M▲ +37.6%46.1%

FY2024$479.1M(11M)$468.4M▲ +25.5%46.1%

FY2023$388.6M(15M)$373.3M▲ +58.6%45.0%

FY2022$240.1M(5M)$235.3M▼ 21.0%35.6%

FY2021$299.4M(1M)$298.0M▲ +462.8%67.2%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

HALO · P/FCF · FCF yield · FCF per share

Halozyme Therapeutics, Inc. (HALO) trades at a FCF yield of 7.92% and a price-to-free-cash-flow ratio of 12.7x. FCF per share stands at $5.57, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

7.92%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$5.57

TTM FCF ÷ Shares Outstanding

Price / FCF

x12.7

Share Price ÷ FCF per Share

EV / FCF (TTM)

x15.4

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

HALO · cash flow statement · operating / investing / financing

For FY2025, Halozyme Therapeutics, Inc. generated $651.6M in operating cash flow and spent 7M in capital expenditures, yielding $644.6M in free cash flow.

Operating Activities

+$651.6M

Cash from core business operations

2025-12-31

Investing Activities

−$545.8M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$85.2M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($651.6M) − |CapEx| (7M) = FCF ($644.6M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

HALO vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Halozyme Therapeutics, Inc.YOU

HALO

$644.6M+37.6%46.2%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Halozyme Therapeutics, Inc. (HALO) reported free cash flow of $644.6M for FY2025 (fiscal year ending 2025-12-31), up 37.6% year-over-year. The FCF margin was 46.1%.

Based on available data, Halozyme Therapeutics, Inc. has maintained positive free cash flow for at least 7 fiscal year(s). FCF peaked at $644.6M in FY2025. The 5-year CAGR stands at +64.8%.

Halozyme Therapeutics, Inc.'s FCF yield is 7.92% and price-to-FCF ratio is 12.7x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

HALO free cash flow · 8 questions

Halozyme Therapeutics, Inc. free cash flow was $644.6M for FY2025, up 37.6% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $667.7M.

HALO free cash flowHALO FCFHALO FCF 2025HALO free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Halozyme Therapeutics, Inc. · Halozyme Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026